Life Science Connect Taps Tech Veteran to Lead Data Revolution

PITTSBURGH, PA – February 25, 2026 – Life Science Connect (“LSC”), a digital media and events company serving the life sciences industry, has appointed B2B intelligence pioneer Don Hawk to its Board of Directors. The move signals a significant strategic acceleration for the Pittsburgh-based company, aiming to infuse the life sciences sector with the sophisticated data-driven marketing and sales intelligence methodologies that have transformed the technology industry.

Backed by private equity firms Latticework Capital Management and Edgehill Management, LSC is positioning itself to capitalize on the growing demand for measurable, insight-led marketing solutions. Hawk’s appointment is the cornerstone of this strategy, bringing decades of experience in building one of the world's most successful B2B intent data platforms to a sector on the cusp of its own data revolution.

A Strategic Push into Data-Driven Insights

The life sciences industry is currently navigating a period of profound transformation. As pharmaceutical, biotech, and medical device companies face mounting pressures to innovate faster and commercialize more efficiently, their marketing and sales functions are moving away from traditional outreach. The new imperative is precision engagement, a trend fueled by the adoption of AI, machine learning, and hyper-personalized communication strategies. Success is no longer just about reaching an audience; it's about understanding their needs, predicting their behavior, and engaging them with relevant content at the exact right moment in their purchasing journey.

Life Science Connect has already laid the groundwork to address this shift. The company operates a network of digital communities and offers services built upon its proprietary Templeton® Customer Insights Platform and Enhanced Lead Intelligence (ELI) reports. These tools are designed to provide clients with behavioral analytics and actionable insights into their target accounts. However, the appointment of Don Hawk indicates a clear ambition to move beyond foundational analytics and build a far more powerful and predictive data engine.

“We’re honored to welcome Don Hawk to the Life Science Connect Board of Directors,” said Jon Howland, CEO of Life Science Connect. “As the founder of TechTarget, Don pioneered the use of behavioral data to identify and share buying intent signals with clients—transforming how B2B organizations align marketing and sales efforts. His experience building data-driven media platforms will provide an important perspective as LSC advances its efforts to strengthen connections across the life sciences industry.”

Hawk's role will be to guide LSC in developing next-generation analytical and lead activation services. The goal is to create a system that not only identifies active buyers but also provides deep intelligence on their specific research interests and challenges, enabling LSC’s clients to tailor their outreach with unprecedented accuracy and drive more meaningful commercial connections.

The TechTarget Playbook Comes to Life Sciences

Don Hawk's 26-year tenure at TechTarget, the company he co-founded in 1999, provides a clear blueprint for what LSC hopes to achieve. Under his leadership as President and later as Executive Director of Product Innovation, TechTarget evolved from a collection of technology-focused websites into a publicly traded, global leader in B2B marketing intelligence. The company’s success was built on a simple but powerful premise: by providing high-quality, independent editorial content, it could attract a qualified audience of technology buyers and then analyze their content consumption patterns to generate valuable purchase intent data.

Hawk was at the heart of this innovation. He was instrumental in the development and launch of TechTarget's first intent data service, "IT Deal Alert," in 2014, and the subsequent "Priority Engine" platform. These products revolutionized B2B tech marketing by giving sales and marketing teams a real-time view into which companies were actively researching solutions, allowing them to prioritize their efforts and engage buyers more intelligently. His work earned him recognition as a "Top Innovator in Business Publishing" and a "Corporate Catalyst" for driving industry innovation.

Now, he is tasked with applying that same playbook to the unique complexities of the life sciences market. While the core principles of tracking user behavior to infer intent remain the same, the context is different. The buying cycles can be longer, the technical subject matter more specialized, and the regulatory environment more stringent. Hawk’s challenge—and LSC’s opportunity—is to adapt and refine this model for the specific needs of scientists, researchers, and executives in the biopharma and medtech fields.

“2026 represents a new chapter for LSC, and I'm excited to be a part of it,” said Mr. Hawk. “The Company has trust-based audience relationships, deep subject matter expertise, a focus on successful client outcomes, and a set of financial partners committed to growth. Great things are ahead for LSC community members and clients, and I'm looking forward to helping the team execute on their growth journey."

The Private Equity Engine Fueling Growth

This strategic pivot is heavily backed by LSC’s financial partners, Latticework Capital Management and Edgehill Management. The appointment of a high-profile industry veteran like Hawk is a classic private equity maneuver designed to accelerate growth and unlock value in a portfolio company. Latticework, a growth-oriented firm exclusively focused on the healthcare industry, employs a "top-down" investment strategy, identifying key industry trends and backing companies positioned to lead them. Their investment in LSC, and the subsequent recruitment of Hawk, demonstrates a strong belief that data-driven marketing is a critical growth vector for the life sciences support ecosystem.

The strategy extends beyond internal product development. The press release explicitly states that LSC is actively "evaluating acquisition and growth opportunities" to expand its capabilities and market reach. Hawk’s experience in identifying and integrating strategic acquisitions at TechTarget will be invaluable in this pursuit. This dual approach of organic innovation and inorganic growth is a hallmark of a private equity-backed scaling strategy, aimed at rapidly consolidating a market position and building a comprehensive, defensible platform.

By bringing in an executive with a proven track record of scaling a data-centric media business, Latticework and Edgehill are not just adding a board member; they are injecting a specific, battle-tested growth methodology into LSC’s DNA. This positions the company to aggressively pursue its mission of becoming the central hub for data-driven connections within the life sciences.

Navigating a Competitive and Evolving Landscape

Life Science Connect does not operate in a vacuum. The B2B life sciences media and events space is populated by a range of competitors, from established news and analysis platforms like Fierce Pharma to specialized event organizers such as Dynamic Global Events (DGE). Many of these players are also investing in data capabilities and digital engagement tools to better serve their clients.

LSC’s strategic bet is that by leveraging Hawk’s expertise, it can leapfrog competitors and establish a new standard for data intelligence in the industry. While others may offer lead generation or basic analytics, LSC aims to build a true intent data platform that provides a holistic view of the buyer’s journey. This deeper level of insight could become a powerful differentiator, offering clients a more efficient and effective path to market.

The success of this strategy will depend on the company's ability to execute on its vision: integrating advanced data analytics with its existing foundation of high-quality content and engaged digital communities. If successful, LSC could transform how companies in the life sciences sector identify, understand, and connect with their most valuable prospects, ultimately fulfilling its mission to accelerate the advancement of life-improving therapies and devices.